8-K Announcements
6Material company update
Feb 20, 2026·SEC
Material company update
Dec 30, 2025·SEC
Material company update
Aug 1, 2025·SEC
MediciNova, Inc.(MNOV)Earnings, Financials & Key Ratios
MNOV•NASDAQ
Price updated Jun 19, 2026
AboutMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.Show more
- Revenue$410K
- EBITDA-$13M-4.8%
- Net Income-$12M-8.6%
- EPS (Diluted)-0.24-4.3%
- Gross Margin7.58%
- EBITDA Margin-3237.56%
- Operating Margin-3242.47%
- Net Margin-2928.78%
- ROE-25.5%-32.6%
MNOV Key Insights
MediciNova, Inc. (MNOV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MNOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MNOV Price & Volume
MediciNova, Inc. (MNOV) stock price & volume — 10-year historical chart
Loading chart...
MNOV Growth Metrics
MediciNova, Inc. (MNOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.86%
Return on Capital
10 Years-22.3%
5 Years-19.29%
3 Years-21.57%
Last Year-28.05%
MNOV Recent Earnings
MediciNova, Inc. (MNOV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$186,984+0.0%
$186,984
Q1 2026
Feb 20, 2026Metric
Actual
Est
EPS
$0.05+47.4%
$0.10
Rev
$151,000-0.5%
$151,739
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.06+25.0%
$0.08
Rev
$123,319
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
$134,599
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.05vs $0.06+16.7% | $186,984vs $186,984+0.0% |
| Q1 2026 | Feb 20, 2026 | $0.05vs $0.10+47.4% | $151,000vs $151,739-0.5% |
| Q4 2025 | Nov 12, 2025 | $0.06vs $0.08+25.0% | $123,319 |
| Q3 2025 | Aug 14, 2025 | $0.07vs $0.07+0.0% | $134,599 |
Based on last 12 quarters of dataView full earnings history →
MNOV Peer Comparison
MediciNova, Inc. (MNOV) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 |
Compare MNOV vs Peers
MediciNova, Inc. (MNOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MNOV Income Statement
MediciNova, Inc. (MNOV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 4.04M | 0 | 1M | 0 | 409.66K | 596.64K |
Revenue Growth % | - | - | - | - | - | -100% | - | -100% | - | - |
Cost of Goods Sold | 28.1K | 25.88K | 23.94K | 0 | 0 | 0 | 0 | 0 | 378.61K | 505.96K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 92.42% | - |
Gross Profit | -28.1K▲ 0% | -25.88K▲ 7.9% | -23.94K▲ 7.5% | 0▲ 100.0% | 4.04M▲ 0% | 0▼ 100.0% | 1M▲ 0% | 0▼ 100.0% | 31.05K▲ 0% | 90.68K▲ 0% |
Gross Margin % | - | - | - | - | 100% | - | 100% | - | 7.58% | 15.2% |
Gross Profit Growth % | -98.9% | 7.89% | 7.48% | 100% | - | -100% | - | -100% | - | - |
Operating Expenses | 13.03M | 15.59M | 14.03M | 14.18M | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M | 13.01M |
OpEx % of Revenue | - | - | - | - | 353.02% | - | 1090.03% | - | 3250.05% | - |
Selling, General & Admin | 8.8M | 9.96M | 7.95M | 6.69M | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M | 1.59B |
SG&A % of Revenue | - | - | - | - | 141.56% | - | 524.24% | - | 1503.5% | - |
Research & Development | 4.22M | 5.63M | 6.08M | 7.49M | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M | 1.27B |
R&D % of Revenue | - | - | - | - | 200.62% | - | 565.83% | - | 1746.55% | - |
Other Operating Expenses | 120.2K | -22.89K | -46.16K | -357 | 438K | 388 | -400 | -413 | 0 | -1.1M |
Operating Income | -13.03M▲ 0% | -15.59M▼ 19.6% | -14.03M▲ 10.0% | -14.18M▼ 1.0% | -10.22M▲ 27.9% | -14.63M▼ 43.2% | -9.9M▲ 32.3% | -12.68M▼ 28.0% | -13.28M▼ 4.8% | -12.92M▲ 0% |
Operating Margin % | - | - | - | - | -253.02% | - | -990.03% | - | -3242.47% | -2164.84% |
Operating Income Growth % | -19.71% | -19.65% | 9.98% | -1.05% | 27.95% | -43.2% | 32.32% | -28.03% | -4.79% | - |
EBITDA | -13M | -15.56M | -14.01M | -14.16M | -10.19M | -14.61M | -9.88M | -12.65M | -13.26M | -12.92M |
EBITDA Margin % | - | - | - | - | -252.38% | - | -988% | - | -3237.56% | -2165.18% |
EBITDA Growth % | -19.61% | -19.71% | 9.99% | -1.07% | 28.02% | -43.39% | 32.38% | -28.08% | -4.81% | -1.55% |
D&A (Non-Cash Add-back) | 28.1K | 25.88K | 23.94K | 21.34K | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K | -2.07K |
EBIT | -12.91M | -15.59M | -14.03M | -14.18M | -10.22M | -14.63M | -9.9M | -12.68M | -11.99M | -12.62M |
Net Interest Income | 0 | 0 | 1.15M | 361.18K | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M | 341.13M |
Interest Income | 0 | 939.91K | 1.15M | 361.18K | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M | 341.13M |
Interest Expense | 298 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 119.91K | 917.01K | 1.1M | 322.78K | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M | 1.2M |
Pretax Income | -12.91M▲ 0% | -14.67M▼ 13.7% | -12.93M▲ 11.9% | -13.86M▼ 7.2% | -10.13M▲ 26.9% | -14.07M▼ 38.8% | -8.57M▲ 39.1% | -11.04M▼ 28.9% | -11.99M▼ 8.6% | -11.71M▲ 0% |
Pretax Margin % | - | - | - | - | -250.94% | - | -856.85% | - | -2927.32% | -1963.34% |
Income Tax | -1.74M | 5.28K | 12.66K | -1.65K | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K | 5.99K |
Effective Tax Rate % | 13.51% | -0.04% | -0.1% | 0.01% | -0.03% | -0.02% | -0.04% | -0.05% | -0.05% | -0.05% |
Net Income | -11.16M▲ 0% | -14.68M▼ 31.5% | -12.94M▲ 11.8% | -13.85M▼ 7.0% | -10.13M▲ 26.8% | -14.07M▼ 38.8% | -8.57M▲ 39.1% | -11.05M▼ 28.9% | -12M▼ 8.6% | -11.72M▲ 0% |
Net Margin % | - | - | - | - | -251% | - | -857.15% | - | -2928.78% | -1964.35% |
Net Income Growth % | -2.73% | -31.46% | 11.81% | -7.05% | 26.85% | -38.83% | 39.08% | -28.91% | -8.58% | -5.03% |
Net Income (Continuing) | -11.16M | -14.68M | -12.94M | -13.85M | -10.13M | -14.07M | -8.57M | -11.05M | -12M | -11.72M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.32▲ 0% | -0.36▼ 12.5% | -0.30▲ 16.7% | -0.31▼ 3.3% | -0.21▲ 32.3% | -0.29▼ 38.1% | -0.17▲ 41.4% | -0.23▼ 35.3% | -0.24▼ 4.3% | -0.24▲ 0% |
EPS Growth % | 3.03% | -12.5% | 16.67% | -3.33% | 32.26% | -38.1% | 41.38% | -35.29% | -4.35% | -2.86% |
EPS (Basic) | -0.32 | -0.36 | -0.30 | -0.31 | -0.21 | -0.29 | -0.17 | -0.23 | -0.24 | - |
Diluted Shares Outstanding | 35.14M | 41.12M | 43.16M | 44.41M | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M | 49.22M |
Basic Shares Outstanding | 35.14M | 41.12M | 43.16M | 44.41M | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M | 49.22M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MNOV Balance Sheet
MediciNova, Inc. (MNOV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 28.33M | 62.76M | 64.3M | 60.72M | 72.01M | 58.99M | 51.17M | 41.07M | 30.99M | 28.15B |
Cash & Short-Term Investments | 27.99M | 62.31M | 63.79M | 60.04M | 71.43M | 58.49M | 51M | 40.36M | 30.81M | 30.81M |
Cash Only | 27.99M | 62.31M | 63.79M | 60.04M | 71.43M | 18.51M | 51M | 40.36M | 30.81M | 30.81M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 39.98M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 245.1M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 37.51K |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 511.92K | 0 | 0 | 0 | 174.94K | 714.54K | 184.83K | 571.54M |
Total Non-Current Assets | 15.09M | 14.46M | 14.9M | 14.7M | 15.4M | 15.17M | 15.1M | 14.8M | 14.61M | 14.56B |
Property, Plant & Equipment | 62.89K | 53.13K | 40.55K | 226.56K | 881.78K | 674.76K | 621.21K | 382.41K | 192.57K | 158.56M |
Fixed Asset Turnover | - | - | - | - | 4.58x | - | 1.61x | - | 2.13x | 0.01x |
Goodwill | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6B |
Intangible Assets | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 0 | 0 |
Long-Term Investments | 616.66K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 10.96K | 10.96K | 459.81K | 75.38K | 115.49K | 92.79K | 74.15K | 19K | 4.82M | 4.8B |
Total Assets | 43.42M▲ 0% | 77.22M▲ 77.9% | 79.21M▲ 2.6% | 75.42M▼ 4.8% | 87.41M▲ 15.9% | 74.15M▼ 15.2% | 66.27M▼ 10.6% | 55.88M▼ 15.7% | 45.6M▼ 18.4% | 42.7B▲ 0% |
Asset Turnover | - | - | - | - | 0.05x | - | 0.02x | - | 0.01x | 0.00x |
Asset Growth % | 9.06% | 77.85% | 2.57% | -4.78% | 15.89% | -15.16% | -10.63% | -15.68% | -18.39% | 81295.36% |
Total Current Liabilities | 2.88M | 2.19M | 2.23M | 2.19M | 2.83M | 3.19M | 3.28M | 2.96M | 3.8M | 3.1B |
Accounts Payable | 1.52M | 616.75K | 451.33K | 616.63K | 402.74K | 424.65K | 1M | 1.1M | 625K | 852.37M |
Days Payables Outstanding | 19.75K | 8.7K | 6.88K | - | - | - | - | - | 602.53 | 154.07K |
Short-Term Debt | 0 | 0 | 216.77K | 0 | 0 | 0 | 0 | 0 | 194.33K | 165.2M |
Deferred Revenue (Current) | 1.69B | 1.69B | 0 | 0 | 0 | 0 | 0 | 0 | 370.16K | 429.17M |
Other Current Liabilities | 0 | 191.93K | 791.65K | 924.3K | 547.27K | 184.1K | 988.76K | 912.78K | 2.61M | 1.65B |
Current Ratio | 9.83x | 28.63x | 28.86x | 27.67x | 25.42x | 18.51x | 15.61x | 13.88x | 8.16x | 9.09x |
Quick Ratio | 9.83x | 28.63x | 28.86x | 27.67x | 25.42x | 18.51x | 15.61x | 13.88x | 8.16x | 9.09x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -116.57K |
Total Non-Current Liabilities | 1.9M | 1.92M | 2.08M | 1.9M | 896.47K | 725.41K | 612.45K | 413.25K | 218.92K | 201.79M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 182.58K | 0 | 694.67K | 523.62K | 0 | 0 | 0 | 191.44K |
Deferred Tax Liabilities | 201.79K | 201.79K | 201.79K | 201.79K | 0 | 0 | 201.79K | 201.79K | 201.79K | 202.4M |
Other Non-Current Liabilities | 0 | 27.21K | 3.78K | 2.71K | 201.79K | 201.79K | 410.66K | 211.46K | 17.13K | 0 |
Total Liabilities | 4.78M | 4.12M | 4.31M | 4.09M | 3.73M | 3.91M | 3.89M | 3.37M | 4.02M | 3.3B |
Total Debt | 0 | 27.21M | 399.35K | 186.03K | 826.64K | 681.12K | 215.93K | 193.77K | 194.33K | 165.2M |
Net Debt | -27.99M | -35.1M | -63.39M | -59.85M | -70.6M | -17.82M | -50.78M | -40.17M | -30.61M | 134.39M |
Debt / Equity | - | 0.37x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -12.79x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -10.40x |
Interest Coverage | -43312.69x | - | - | - | - | - | - | - | - | - |
Total Equity | 38.64M▲ 0% | 73.11M▲ 89.2% | 74.89M▲ 2.4% | 71.33M▼ 4.8% | 83.68M▲ 17.3% | 70.24M▼ 16.1% | 62.38M▼ 11.2% | 52.5M▼ 15.8% | 41.59M▼ 20.8% | 39.41B▲ 0% |
Equity Growth % | 11.9% | 89.19% | 2.44% | -4.76% | 17.32% | -16.06% | -11.2% | -15.83% | -20.79% | 78764.88% |
Book Value per Share | 1.10 | 1.78 | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | 1.07 | 0.85 | 800.61 |
Total Shareholders' Equity | 38.64M | 73.11M | 74.89M | 71.33M | 83.68M | 70.24M | 62.38M | 52.5M | 41.59M | 39.41B |
Common Stock | 36.45K | 42.08K | 43.91K | 45.02K | 49.04K | 49.05K | 49.05K | 49.05K | 49.22K | 49.22M |
Retained Earnings | -341.46M | -356.13M | -369.07M | -382.93M | -393.06M | -407.13M | -415.7M | -426.75M | -438.75M | -441.34B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -94.62K | -93.15K | -92.68K | -88.22K | -98.88K | -115.28K | -118.09K | -135.15K | -127.18K | -128.13M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MNOV Cash Flow Statement
MediciNova, Inc. (MNOV) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.92M | -9.11M | -9.12M | -10.83M | -9.38M | -12.91M | -7.43M | -10.64M | -9.81M | -9.5M |
Operating CF Margin % | - | - | - | - | -232.36% | - | -743.1% | - | -2394.7% | - |
Operating CF Growth % | -5.77% | -31.63% | -0.12% | -18.65% | 13.34% | -37.63% | 42.45% | -43.22% | 7.83% | 38.01% |
Net Income | -11.16M | -14.68M | -12.94M | -13.85M | -10.13M | -14.07M | -8.57M | -11.05M | -12M | -11.72M |
Depreciation & Amortization | 28.1K | 25.88K | 23.94K | 21.34K | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K | 59.73K |
Stock-Based Compensation | 4.47M | 6.33M | 4.11M | 3.18M | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K | 543.15K |
Deferred Taxes | -1.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.9M | -19.87K | 0 | 210.21K | 216.93K | 163.19K | 297.49K | 173.32K | 878.83K | 1.24M |
Working Capital Changes | -265.51K | -775.35K | -319.92K | -379.57K | -1.21M | 334.1K | 111.99K | -979.56K | 459.87K | 379.53K |
Change in Receivables | 242.06K | -111.68K | -514.02K | 0 | 0 | 0 | 0 | 0 | 0 | -245.1K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.25M | -663.67K | 194.1K | -4.77K | -1.03M | 329.01K | 19.24K | -312.35K | 459.87K | 537.67K |
Cash from Investing | -84.48M | 626.32K | -11.27K | -36.49K | -28.73K | -40.01M | 39.91M | -697 | -2.9K | -13.72K |
Capital Expenditures | 0 | -10.2K | -11.27K | -36.49K | -28.73K | -5.01K | -21.3K | -895 | 0 | -10.82K |
CapEx % of Revenue | - | - | - | - | 0.71% | - | 2.13% | - | - | 1.81% |
Acquisitions | 0 | 636.52K | 0 | 0 | 0 | 5.01M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -84.48M | 636.52K | 0 | 0 | 0 | -5.01M | 0 | 198 | -2.9K | -2.9K |
Cash from Financing | 10.8M | 42.81M | 10.62M | 7.11M | 20.78M | 7.92K | 0 | 0 | 244.02K | 244.02K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 10.72M | 42.76M | 10.88M | 7.3M | 20.89M | 7.92K | 0 | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 77.32K | 51.01K | -261.05K | -192.13K | -112.26K | 0 | 0 | 0 | 244.02K | 244.02K |
Net Change in Cash | 3.87M▲ 0% | 34.32M▲ 786.0% | 1.48M▼ 95.7% | -3.76M▼ 353.9% | 11.39M▲ 403.4% | -52.93M▼ 564.5% | 32.49M▲ 161.4% | -10.64M▼ 132.7% | -9.55M▲ 10.2% | -9.24M▲ 0% |
Free Cash Flow | -6.92M▲ 0% | -9.12M▼ 31.8% | -9.14M▼ 0.1% | -10.86M▼ 18.9% | -9.41M▲ 13.4% | -12.92M▼ 37.3% | -7.45M▲ 42.3% | -10.64M▼ 42.8% | -9.81M▲ 7.8% | -9.51M▲ 0% |
FCF Margin % | - | - | - | - | -233.07% | - | -745.23% | - | -2394.7% | -1593.49% |
FCF Growth % | -4.42% | -31.78% | -0.13% | -18.9% | 13.37% | -37.26% | 42.3% | -42.83% | 7.83% | 9.96% |
FCF per Share | -0.20 | -0.22 | -0.21 | -0.24 | -0.19 | -0.26 | -0.15 | -0.22 | -0.20 | -0.19 |
FCF Conversion (FCF/Net Income) | 0.62x | 0.62x | 0.71x | 0.78x | 0.93x | 0.92x | 0.87x | 0.96x | 0.82x | 0.81x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 9.2K | 6K | 11.27K | 1.49K | 0 | 0 | 3.67K | 5.04K | 0 | 0 |
MNOV Key Ratios
MediciNova, Inc. (MNOV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -30.51% | -26.26% | -17.49% | -18.95% | -13.08% | -18.28% | -12.93% | -19.24% | -25.5% | -0.12% |
Return on Invested Capital (ROIC) | -88.69% | -48.05% | -42.51% | -92.56% | -62.42% | -33.51% | -23.2% | -79.44% | -85.47% | -0.1% |
Gross Margin | - | - | - | - | 100% | - | 100% | - | 7.58% | 15.2% |
Net Margin | - | - | - | - | -251% | - | -857.15% | - | -2928.78% | -1964.35% |
Debt / Equity | - | 0.37x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Interest Coverage | -43312.69x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 0.62x | 0.62x | 0.71x | 0.78x | 0.93x | 0.92x | 0.87x | 0.96x | 0.82x | 0.81x |
Revenue Growth | - | - | - | - | - | -100% | - | -100% | - | - |
Related:MNOV Dividend History·MNOV Revenue History·MNOV Price History·MNOV P/E History·MNOV Financial Ratios·MNOV Institutional Holders
MNOV SEC Filings & Documents
MediciNova, Inc. (MNOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
MNOV Frequently Asked Questions
MediciNova, Inc. (MNOV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MediciNova, Inc. (MNOV) reported $0.6M in revenue for fiscal year 2025.
MediciNova, Inc. (MNOV) grew revenue by 0.0% over the past year. Growth has been modest.
MediciNova, Inc. (MNOV) reported a net loss of $11.7M for fiscal year 2025.
Dividend & Returns
MediciNova, Inc. (MNOV) has a return on equity (ROE) of -25.5%. Negative ROE indicates the company is unprofitable.
MediciNova, Inc. (MNOV) had negative free cash flow of $9.5M in fiscal year 2025, likely due to heavy capital investments.